SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety

Table 4 Multi-factor Cox regression analysis

Variable	Z	HR (95%CI)	P value
Differentiation
Well		Reference
Moderate	1.573	1.516 (0.903, 2.545)	0.116
Poorly	2.678	1.848 (1.179, 2.896)	0.007
cN stage
Negative		Reference
Positive	2.872	1.794 (1.204, 2.672)	0.004
cTNM
II		Reference
IIIA	1.100	1.493 (0.731, 3.048)	0.271
IIIB	4.213	2.477 (1.625, 3.778)	< 0.001
IIIC	5.834	3.750 (2.405, 5.846)	< 0.001
RECIST 1.1
Ineffective		Reference
Effective	-3.259	0.574 (0.411, 0.802)	0.001
TRG
Ineffective		Reference
Effective	2.580	2.008 (1.182, 3.410)	0.010
Tumor diameter
≤ 2		Reference
2-5	3.453	1.974 (1.342, 2.903)	0.001
≥ 5	5.282	3.145 (2.056, 4.811)	< 0.001

RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor regression grade.